Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 5:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 30 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Bronchoconstriction Clear all
Terminated Phase 3 Interventional Results available

A Twelve Month Long Term Safety Study to Evaluate the Safety of Albuterol in a Dry Powder Inhaler With Both Repeated and as Needed Dosing

NCT01218009
View directory record Official record
Conditions
Asthma
Interventions
Placebo Spiromax, Albuterol Spiromax
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
30
States / cities
Scottsdale, Arizona • Los Angeles, California • San Diego, California + 27 more
Source: ClinicalTrials.gov public record
Updated May 19, 2015 · Synced Sep 3, 2026, 5:03 AM EDT
Terminated Phase 3 Interventional

Single-Dose Cross-Over Study of the Effects of Albuterol-HFA in Exercise Induced Bronchoconstriction

NCT00634829
View directory record Official record
Conditions
Asthma, Bronchospasm
Interventions
albuterol (Armstrong Albuterol HFA), Albuterol Sulfate (Provenetil-HFA), Placebo-HFA
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
3
States / cities
Denver, Colorado • Englewood, Colorado • Lakewood, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 14, 2013 · Synced Sep 3, 2026, 5:03 AM EDT
Completed Phase 3 Interventional

Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma

NCT00073840
View directory record Official record
Conditions
Asthma
Interventions
levalbuterol
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
54
States / cities
Oxford, Alabama • Tucson, Arizona • Corona, California + 49 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2012 · Synced Sep 3, 2026, 5:03 AM EDT
Completed Phase 3 Interventional

Dose Response Study of Levalbuterol in the Prevention of Exercise Induced Bronchoconstriction Compared to Racemic Albuterol

NCT00685425
View directory record Official record
Conditions
Asthma, Bronchoconstriction
Interventions
Levalbuterol HFA MDI, Racemic Albuterol
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
5
States / cities
Los Angeles, California • Signal Hill, California • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2012 · Synced Sep 3, 2026, 5:03 AM EDT
Completed Phase 4 Interventional

Dose Response Effects of Inhaled Fluticasone on Airway Effects of Hypertonic-saline in Asthma

NCT00606242
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2014 · Synced Sep 3, 2026, 5:03 AM EDT
Not yet recruiting Phase 1 Interventional

ADO-5030 in Bronchoconstriction Challenge, Phase 1b

NCT07281274
View directory record Official record
Conditions
Asthma (Diagnosis)
Interventions
ADO-5030
Drug
Lead sponsor
Adovate
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 3, 2026, 5:03 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Reducing Exercise-induced Bronchoconstriction in Children With Asthma and Obesity

NCT03586544
View directory record Official record
Conditions
Asthma in Children, Obesity, Childhood, Exercise Induced Bronchospasm
Interventions
Albuterol Sulfate, Interval Warm-up exercise
Drug · Behavioral
Lead sponsor
University of Nevada, Las Vegas
Other
Eligibility
8 Years to 12 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Sep 3, 2026, 5:03 AM EDT
Completed Phase 2 Interventional

A Placebo and Active Controlled Study of ONO-6950 in Asthmatic Patients

NCT01536041
View directory record Official record
Conditions
Asthma
Interventions
ONO-6950, Montelukast, Placebo
Drug
Lead sponsor
Ono Pharma USA Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
9
States / cities
Los Angeles, California • San Diego, California • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Sep 3, 2026, 5:03 AM EDT
Completed Phase 4 Interventional

The Effect of Cetirizine on Bronchoconstriction

NCT03340740
View directory record Official record
Conditions
Allergic Rhinitis, Asthma
Interventions
Cetirizine Hydrochloride 1 MG/ML, Placebo - Concentrate
Drug
Lead sponsor
New York City Health and Hospitals Corporation
Other
Eligibility
6 Years to 20 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Sep 3, 2026, 5:03 AM EDT
Completed Not applicable Interventional

Effect of a Component of Fish Oil on Exercise-Induced Bronchoconstriction and Airway Inflammation in Asthma

NCT01504646
View directory record Official record
Conditions
Asthma, Exercise-Induced Bronchoconstriction
Interventions
Lyprinol, Placebo (Olive Oil)
Dietary Supplement
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 30 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 22, 2018 · Synced Sep 3, 2026, 5:03 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of Inhaled Albuterol Spiromax® in Subjects With Persistent Asthma With Steady State Pharmacokinetics

NCT01747629
View directory record Official record
Conditions
Asthma
Interventions
Placebo MDPI, Albuterol MDPI
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
35
States / cities
Costa Mesa, California • Encinitas, California • Huntington Beach, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2015 · Synced Sep 3, 2026, 5:03 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effectiveness of Ipratropium Bromide in Preventing Exercise-induced Bronchoconstriction in Athletes

NCT01691079
View directory record Official record
Conditions
Bronchospasm, Exercise-Induced
Interventions
ipratropium bromide, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
13 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Sep 3, 2026, 5:03 AM EDT
Completed Not applicable Interventional Results available

Relief of Acute Bronchoconstriction/Asthma Using the Non-Invasive AlphaCore Device

NCT01532817
View directory record Official record
Conditions
Asthma
Interventions
AlphaCore
Device
Lead sponsor
ElectroCore INC
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
3
States / cities
San Diego, California • Minneapolis, Minnesota • Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 8, 2018 · Synced Sep 3, 2026, 5:03 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of Albuterol SPIROMAX® in Adult and Adolescent Patients With Exercise-Induced Bronchoconstriction (EIB)

NCT01791972
View directory record Official record
Conditions
Exercise-Induced Bronchoconstriction (EIB)
Interventions
Albuterol Spiromax, Placebo Spiromax
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
6
States / cities
San Diego, California • Denver, Colorado • Wheaton, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2015 · Synced Sep 3, 2026, 5:03 AM EDT
Completed Phase 1 Interventional

A Cumulative Dose Study to Evaluate the Safety and Efficacy of Albuterol in a Dry Powder Inhaler and an HFA MDI (Hydrofluoroalkane Metered Dose Inhaler)

NCT01056159
View directory record Official record
Conditions
Asthma
Interventions
Albuterol dry powder inhaler, Albuterol HFA MDI (hydrofluoroalkane metered dose inhaler)
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
9
States / cities
Los Angeles, California • Denver, Colorado • Lakewood, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Sep 3, 2026, 5:03 AM EDT
Completed Phase 3 Interventional

Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma

NCT00073827
View directory record Official record
Conditions
Asthma
Interventions
levalbuterol tartrate MDI, racemic albuterol MDI, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
63
States / cities
Homewood, Alabama • Mobile, Alabama • Corona, California + 55 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2012 · Synced Sep 3, 2026, 5:03 AM EDT
Completed Phase 2 Interventional

Dose Response Study of Levalbuterol in the Prevention of Exercise Induced Bronchoconstriction Compared to Racemic Albuterol in Pediatric Subjects

NCT00685347
View directory record Official record
Conditions
Asthma, Bronchoconstriction
Interventions
Levalbuterol HFA MDI, Racemic Albuterol
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
6
States / cities
Long Beach, California • Denver, Colorado • Englewood, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2012 · Synced Sep 3, 2026, 5:03 AM EDT
Completed Phase 1 Interventional

Effect of Fish Oil and Vitamin C on Exercise-Induced Bronchoconstriction and Airway Inflammation in Asthma

NCT01057615
View directory record Official record
Conditions
Asthma
Interventions
Fish Oil, Ascorbic Acid, Fish Oil Placebo, Ascorbic Acid Placebo
Dietary Supplement
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 40 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 30, 2011 · Synced Sep 3, 2026, 5:03 AM EDT
Completed Phase 2 Interventional Results available

A Clinical Trial to Test a Study Drug in Volunteers Who Develop Asthma Following Exercise

NCT00812929
View directory record Official record
Conditions
Asthma
Interventions
Placebo, GSK2190915
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Denver, Colorado • North Dartmouth, Massachusetts • Oklahoma City, Oklahoma + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2017 · Synced Sep 3, 2026, 5:03 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) on Exercise-induced Bronchoconstriction in Adults and Adolescents With Asthma

NCT04234464
View directory record Official record
Conditions
Exercise Induced Bronchospasm
Interventions
Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg, Placebo metered-dose inhaler
Combination Product
Lead sponsor
Bond Avillion 2 Development LP
Industry
Eligibility
12 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
6
States / cities
Denver, Colorado • North Dartmouth, Massachusetts • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2022 · Synced Sep 3, 2026, 5:03 AM EDT
Completed Phase 4 Interventional Results available

Crossover Study Comparing Fluticasone Furoate (FF)/Vilanterol (VI) Once Daily Versus Fluticasone Propionate (FP) Twice Daily in Subjects With Asthma and Exercise-Induced Bronchoconstriction (EIB)

NCT02730351
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone furoate/ Vilanterol 100 mcg/25 mcg, Fluticasone propionate 250 mcg, Placebo via ELLIPTA inhaler, Placebo via DISKUS / ACCUHALER
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 50 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
13
States / cities
Huntington Beach, California • Los Angeles, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Sep 3, 2026, 5:03 AM EDT
Completed Not applicable Interventional Results available

Inspiratory Muscle Training on The Severity of Exercise-Induced Bronchoconstriction and Time-Trial Performance (IMT_EIB)

NCT06336681
View directory record Official record
Conditions
Exercise Induced Bronchospasm, Exercise Induced Asthma
Interventions
PrO2Fit Device
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 35 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 3, 2026, 5:03 AM EDT
Withdrawn Not applicable Interventional

Vitamin C & Exercise Induced Bronchoconstriction (EIB)

NCT03610932
View directory record Official record
Conditions
Exercise-induced Bronchospasm
Interventions
Vitamin C, Placebo
Dietary Supplement · Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Sep 3, 2026, 5:03 AM EDT